Clinical Trials Browser

NCT07223047 2026-03-17

A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies

Phase 1/2 Recruiting

252 enrolled

GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms

NCT03424005 2026-03-16

Morpheus-panBC

Phase 1/2 Recruiting

792 enrolled

Breast

Breast Neoplasms

NCT06445062 2026-03-13

Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors

Phase 1/2 Recruiting

1,130 enrolled

Gastrointestinal

Gastrointestinal Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms, Carcinoma, Pancreatic Ductal

NCT07020221 2026-03-09

A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors

Phase 1/2 Recruiting

295 enrolled

GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Gastrointestinal Neoplasms, Lung Neoplasms, Neoplasm Metastasis, Pancreatic Neoplasms, Colorectal Neoplasms

NCT03652428 2026-03-02

Phase I Nab-Paclitaxel Plus Gemcitabine With Proton Therapy for Locally Advanced Pancreatic Cancer (LAPC)

Phase 1/2 Recruiting

24 enrolled

Gastrointestinal

Locally Advanced Pancreatic Cancer

NCT06996782 2026-02-24

ALTAIR

Phase 1/2 Recruiting

152 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT07296341 2026-01-14

HRS-4642 Combination With Other Antitumor Therapies in Patients With Solid Tumors

Phase 1/2 Recruiting

60 enrolled

Gastrointestinal

Locally Advanced or Metastatic Pancreatic Cancer With

NCT06741644 2026-01-09

A Phase I/II Study of CS2009 in Participants With Advanced Solid Tumors

Phase 1/2 Recruiting

660 enrolled

Other solid neoplasm

Advanced Solid Tumors

NCT04711824 2025-12-23

SOLARA

Phase 1/2 Recruiting

41 enrolled

BreastCNS

Brain Neoplasms, Breast Neoplasms

NCT05431270 2025-01-31

Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 MAb, Administered Alone and in Combination with a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study)

Phase 1/2 Recruiting

40 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

NCT05218889 2024-12-31

Surufatinib Plus Camrelizumab and AS in First Line Treatment of Advanced Metastatic Pancreatic Cancer

Phase 1/2 Recruiting

90 enrolled

Gastrointestinal

Pancreatic Neoplasms

NCT04278287 2024-12-13

Chemoradiotherapy in Unresectable Esophageal Cancer

Phase 1/2 Recruiting

105 enrolled

Gastrointestinal

Esophageal Neoplasms

NCT05501665 2024-10-17

Split Course Adaptive Radiation Therapy With Pembrolizumab With/Without Chemotherapy for Treating Stage IV Lung Cancer

Phase 1/2 Recruiting

25 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT05064618 2024-04-04

MIKE-1

Phase 1/2 Recruiting

55 enrolled

Gastrointestinal

Pancreatic Neoplasms

NCT06173986 2023-12-18

Immunotherapy in Combination With Chemoradiotherapy in Unresectable Locally Advanced Esophageal Cancer

Phase 1/2 Recruiting

50 enrolled

Gastrointestinal

Esophageal Squamous Cell Carcinoma

NCT05981001 2023-08-08

Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes for Advanced HER2-Negative Breast Cancer

Phase 1/2 Recruiting

170 enrolled

Breast

Breast Neoplasms

NCT05981014 2023-08-08

Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes as Neoadjuvant Therapy for HER2-Negative Breast Cancer

Phase 1/2 Recruiting

196 enrolled

Breast

Breast Neoplasms